サンプル依頼リスト カート
  • English
  • Korean
表紙：肺炎治療薬の世界市場-2023年～2030年
市場調査レポート
商品コード
1347973

肺炎治療薬の世界市場-2023年～2030年

Global Pneumonia Therapeutics Market - 2023-2030
出版日: | 発行: DataM Intelligence | ページ情報: 英文 195 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
肺炎治療薬の世界市場-2023年～2030年
出版日: 2023年09月11日
発行: DataM Intelligence
ページ情報: 英文 195 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

概要

肺炎は、細菌、ウイルス、真菌の感染によって引き起こされる肺の炎症と液体の貯留を特徴とします。細菌性肺炎はウイルス性肺炎よりも一般的で重症化する傾向があります。肺炎は一般的な疾患であり、米国では毎年数百万人が罹患しています。

世界の肺炎治療薬市場は、肺炎の治療薬として認可されているセフトロザン／タゾバクタム製剤が8時間ごとに3gの用量で使用されていることから、近年大きな成長を遂げています。肺炎の症状には、粘液の有無にかかわらず咳、発熱、悪寒、呼吸困難など、軽度なものから重篤なものまです。

さらに、製品承認の増加や研究開発などの重要な成長要因が、将来の市場開拓をもたらします。Pfizer Inc.、LGM Pharma LLC、Teva Pharmaceuticals Ltd.、Sanofi S.A.、Baxter International Inc.などの主要企業がこの市場で活発に活動しています。

市場力学

肺炎治療薬の承認増加

肺炎に感染すると呼吸が困難になり、発熱や黄色、緑色、または血の混じった粘液を伴う咳が出ることがあります。大手企業による製品承認は市場成長の原動力となり、こうした製品承認は新たな治療法の獲得や何百万人もの肺炎感染者のケア改善に役立っています。

例えば、2023年5月、Innoviva Specialty Therapeutics, Inc.は、米国食品医薬品局（FDA）がXACDUROを院内細菌性肺炎および人工呼吸器関連細菌性肺炎の治療薬として、18歳以上の患者への静脈内使用のために共同包装することを承認したと発表しました。

さらに2023年1月、アルケム・ラボラトリーズはセフタジジムとアビバクタムの新規配合剤である抗生物質製剤ジダビを発売しました。ジダビは複雑性尿路感染症など様々な疾患に適応があり、院内肺炎（HAP）ではメロペネムやコリスチンの効果的な代替薬となります。したがって、上記の要因により、市場は予測期間中に拡大すると予想されます。

肺炎治療のための技術進歩の拡大

世界の肺炎治療薬市場は、最近のさまざまな技術進歩により大きな成長を遂げています。肺炎は通常、病歴や臨床所見、画像所見に基づいて診断されます。また、重症肺炎の治療における高度な技術の進歩は、市場の成長を加速させるのに役立っています。

例えば、2022年12月、スウォンジー大学の研究チームは、緊急の集中治療と人工呼吸器サポートが必要な肺炎患者の治療の優先順位付けを支援する「デジタルツイン」と呼ばれるAI-ENABLED SYSTEMを開発しました。この新しい革新的なシステムは、過去の肺炎患者のデータに基づいて、より迅速に診察され、最も効果的な治療を受けられる可能性があります。また、心拍数や呼吸数といった患者のバイタルデータを定期的に入力することで、現在の既知の状態から患者の健康状態がどのように変化するかをリアルタイムでフィードバックすることもできます。

抗生物質に伴う副作用が世界市場の成長を妨げると予想される

肺炎の治療に一般的に使用される抗生物質には複数の種類があり、不快な副作用を伴うことがあります。これには、吐き気、嘔吐、下痢、胃のむかつき、食欲不振、粘土色の便、胃痛などの胃腸障害が含まれます。また、じんましんのような皮膚の問題、口腔鵞口瘡を含むイースト菌感染症、アレルギー反応を引き起こすこともあります。したがって、上記の要因が市場成長の妨げになると予想されます。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 肺炎治療における製品承認の増加
      • 肺炎治療における技術進歩の拡大
    • 抑制要因
      • 抗生物質による副作用
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターの5フォース分析
  • サプライチェーン分析
  • アンメットニーズ
  • 規制分析
  • DMI意見

第6章 COVID-19分析

第7章 タイプ別

  • 市中肺炎
    • 細菌性肺炎
    • ウイルス性肺炎
    • 真菌性肺炎
  • 院内肺炎
  • ヘルスケア関連肺炎
  • 人工呼吸器関連肺炎
  • 誤嚥性肺炎

第8章 治療法別

  • 予防ワクチン
  • 抗菌薬
    • デラフロキサシン（バクデラ）
    • アジスロマイシン（ジスロマック）
    • アズトレオナム（アザクタム）
    • エルタペネム（インバンツ）
    • その他
  • 抗真菌薬
    • イトラコナゾール
    • フルコナゾール
    • トリアゾール系
    • その他
  • 抗ウイルス薬
    • リバビリン
    • アマンタジン
    • アシクロビル
    • その他

第9章 投与経路別

  • 経口
  • 非経口
  • その他

第10章 流通チャネル別

  • 病院薬局
  • 小売薬局
  • オンライン薬局

第11章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋
  • 中東・アフリカ

第12章 競合情勢

  • 競合シナリオ
  • 製品ベンチマーク
  • 企業シェア分析
  • 主な動向と戦略

第13章 企業プロファイル

  • Pfizer Inc.
    • 企業概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な動向
  • Dr. Reddy's Laboratories
  • LGM Pharma LLC
  • Teva Pharmaceuticals Ltd.
  • AdvaCare Pharma
  • Baxter International Inc.
  • Innoviva Specialty Therapeutics Inc.
  • F. Hoffmann-La Roche Ltd
  • Sanofi S.A
  • Lupin Limited

第14章 付録

目次
Product Code: PH1406

Overview

Pneumonia is characterized by inflammation and fluid accumulation in the lungs which is caused by a bacterial, viral, or fungal infection. Bacterial pneumonia tends to be more common and more severe than viral pneumonia. Pneumonia is a common illness, with millions of people diagnosed each year in the United States.

The global pneumonia therapeutics market has witnessed significant growth in recent years due to the usage of the Ceftolozane/tazobactam drug that is licensed for the treatment of pneumonia at a dosage of 3 g every 8 hours. Pneumonia symptoms can range from mild to serious which include a cough with or without mucus, fever, chills, and trouble breathing.

Furthermore, significant growth drivers such as increasing product approvals, and research and developments give rise to future market growth. Significant key players like Pfizer Inc., LGM Pharma LLC, Teva Pharmaceuticals Ltd., Sanofi S.A, Baxter International Inc., and others are actively operating in the market.

Market Dynamics

Rising product approvals for pneumonia treatment

Pneumonia infection makes it difficult to breathe and can cause a fever and cough with yellow, green, or bloody mucus. The product approvals by major companies help to drive market growth and these product approvals help in getting new treatments and improve care for millions of people with pneumonia infections.

For instance, in May 2023, Innoviva Specialty Therapeutics, Inc. declared that the U.S. Food and Drug Administration (FDA) approved XACDURO co-packaged for intravenous use in patients 18 years of age and older for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.

Additionally, in January 2023, Alkem Laboratories launched an antibiotic drug Zidavi, a novel combination of ceftazidime and avibactam which is indicated for various ailments like complicated urinary tract infections and as an effective alternative to meropenem and colistin in hospital-acquired pneumonia (HAP). Thus, owing to the above factors the market is expected to boost over the forecast period.

Increasing technological advancements for pneumonia treatment

The global pneumonia therapeutics market has witnessed significant growth due to various recent technological advancements. Pneumonia is usually diagnosed on the basis of medical history and clinical and imaging findings. Also, advanced technological advancements in treating severe pneumonia cases help to accelerate market growth.

For instance, in December 2022, a research team at Swansea University developed an AI-ENABLED SYSTEM called 'digital twin' to help prioritize treatment for pneumonia patients who require urgent intensive care and ventilator support. This new innovative system is potentially seen more quickly and receives the most effective treatment based on data from previous pneumonia sufferers. It can also provide real-time feedback on how a patient's health is likely to vary based on their current known condition using periodic input data from the patient's vitals such as heart rate, and respiration rate.

Side effects associated with antibiotic drugs are expected to hamper global market growth

There are multiple types of antibiotics that commonly used to treat pneumonia infections and and can have some uncomfortable side effects. These can include gastrointestinal discomfort such as nausea, vomiting, diarrhea, upset stomach, loss of appetite, clay-colored stools, and stomach pain. It can also cause skin issues like hives, yeast infections including oral thrush, and allergic reactions. Thus, the above factors are expected to hamper the market growth.

Segment Analysis

The global pneumonia therapeutics market is segmented based on type, treatment, route of administration, distribution channel, and region.

Antibacterial Drugs are expected to hold the largest market share over the period forecast owing to increasing clinical trials of bacterial pneumonia treatment drugs. A total of 324 clinical trials were performed for the treatment of community-acquired pneumonia. For instance, according to clinicalTrials.gov, on July 3, 2023, Paratek Pharmaceuticals Inc. conducted a clinical trial on Omadacycline vs. Moxifloxacin for the Treatment of Community-Acquired Bacterial Pneumonia. The purpose of this study is to evaluate the safety and efficacy of omadacycline as compared to moxifloxacin in the treatment of adults with community-acquired bacterial pneumonia. The intervention include antibacterial drug Omadacycline and Moxifloxacin IV for injection, and oral tablets.

Additionally, on March 8, 2023, Evopoint Biosciences Inc., conducted a clinical trial on Imipenem/Cilastatin-XNW4107 Versus Imipenem/Cilastatin/Relebactam for Treatment of Participants with Bacterial Pneumonia. The study aims to compare treatment with Imipenem/Cilastatin-XNW4107 (IMI-XNW4107) with imipenem/cilastatin/relebactam (IMI/REL) in participants with hospital-acquired or ventilator-associated bacterial pneumonia.

Geographical Penetration

North America accounted for approximately 38.4% of the market share in 2022

The global pneumonia therapeutics market is segmented into North America, Europe, Asia Pacific, South America, Middle East, and Africa. North America has maintained a significant proportion of the pneumonia therapeutics market in recent years, and this trend is anticipated to continue throughout the forecast period due to factors such as the rising incidence of pneumonia diseases, product approvals, and research and developments in pneumonia therapeutics.

For instance, according to the Centers for Disease Control and Prevention 2022, pneumococcal pneumonia causes an estimated 150,000 hospitalizations each year in the United States. The number of visits to emergency departments with pneumonia as the primary diagnosis is 1.5 million and 50,000 deaths from pneumonia disease every year.

In June 2023, Eagle Pharmaceuticals, Inc. declared that the U.S. Food and Drug Administration (FDA) has granted Qualified Infectious Disease Product (QIDP) Designation under the Generating Antibiotic Incentives Now (GAIN) Act and Fast Track Designation for CAL02, a first-in-class non-biological bacterial virulence neutralizer, anti-infective agent being developed to treat severe community-acquired bacterial pneumonia (SCABP) as an add-on therapy to standard of care.

Additionally, in June 2021, The FDA has approved omadacycline, an oral-only dosing regimen, for the treatment of community-acquired bacterial pneumonia. Omadacycline is a novel antibiotic with once-daily oral and IV formulations for the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections.

COVID-19 Impact Analysis

The COVID-19 pandemic has had a significant impact on the global pneumonia therapeutics treatment market. During the height of the pandemic, many healthcare systems were overwhelmed, and non-urgent medical procedures and screenings were postponed or canceled. This led to delays in pneumonia therapeutics research and product launches. Clinical trials are vital for developing new treatments and improving outcomes in the pneumonia therapeutics market.

However, the pandemic disrupted the conduct of clinical trials, with many sites temporarily halting enrollment or modifying protocols to prioritize patient safety. This has led to delays in the completion of trials and the availability of new therapies. Moreover, the focus of research and development efforts shifted during the pandemic, with a significant emphasis on developing vaccines and treatments for COVID-19. Therefore, owing to the above factors, the pneumonia therapeutics market is expected to be moderately affected over the forecast period.

Market Segmentation:

By Type

  • Community-acquired Pneumonia
    • Bacterial Pneumonia
    • Viral Pneumonia
  • Fungal Pneumonia
    • Hospital-acquired Pneumonia
    • Healthcare-associated Pneumonia
    • Ventilator-associated Pneumonia
    • Aspiration Pneumonia

By Treatment

  • Prevention Vaccines
  • Antibacterial Drugs
    • Delafloxacin (Baxdela)
    • Azithromycin (Zithromax)
    • Aztreonam (Azactam)
    • Ertapenem (Invanz)
    • Others
  • Antifungal Drugs
    • Itraconazole
    • Fluconazole
    • Triazoles
    • Others
  • Antiviral Drugs
    • Ribavirin
    • Amantadine
    • Acyclovir
    • Others

By Route of Administration

  • Oral
  • Parenteral
  • Others

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa

Competitive Landscape

The major global players in the market include: Pfizer Inc., Dr. Reddy's Laboratories, LGM Pharma LLC, Teva Pharmaceuticals Ltd., AdvaCare Pharma, Baxter International Inc., Innoviva Specialty Therapeutics Inc., F. Hoffmann-La Roche Ltd, Sanofi S.A, Lupin Limited among others.

Key Developments

  • In January 2023, Aeolian Biotech Corp. launched an improved pneumococcal conjugate vaccine, 'iPCV22', to address the threat of circulating and emerging pneumococcal serotypes. Aeolian's iPCV22 vaccine potentially covers 95 percent of invasive pneumococcal disease in adults.
  • In May 2023, Gates Foundation funded $200M to develop affordable childhood vaccines and to support delivery of vaccines to prevent pneumonia, meningitis, and neonatal sepsis.
  • In June 2023, Aridis Pharmaceuticals, Inc. reported that its AR-301 clinical program is being considered for availing the FDA's Limited Population Pathway for Antibacterial and Antifungal Drugs. AR-301, ARDS' proprietary monoclonal antibody candidate was developed as an adjunctive therapy to be implemented along with standard-of-care antibiotics for the treatment of pneumonia caused by Gram-positive bacteria, Staphylococcus aureus.

Why Purchase the Report?

  • To visualize the global pneumonia therapeutics market segmentation based on type, treatment, route of administration, distribution channel, and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of global pneumonia therapeutics market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global pneumonia therapeutics market report would provide approximately 69 tables, 71 figures, and 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Type
  • 3.2. Snippet by Treatment
  • 3.3. Snippet by Route of Administration
  • 3.4. Snippet by Distribution Channel
  • 3.5. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rising product approvals for pneumonia treatment
      • 4.1.1.2. Increasing technological advancements for pneumonia treatment
    • 4.1.2. Restraints
      • 4.1.2.1. Side effects associated with antibiotic drugs.
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's 5 Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Unmet Needs
  • 5.4. Regulatory Analysis
  • 5.5. DMI Opinion

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID-19
    • 6.1.2. Scenario During COVID-19
    • 6.1.3. Scenario Post COVID-19
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturers' Strategic Initiatives
  • 6.6. Conclusion

7. By Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 7.1.2. Market Attractiveness Index, By Type
  • 7.2. Community-acquired Pneumonia*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 7.2.3. Bacterial Pneumonia
    • 7.2.4. Viral Pneumonia
    • 7.2.5. Fungal Pneumonia
  • 7.3. Hospital-acquired Pneumonia
  • 7.4. Healthcare-associated Pneumonia
  • 7.5. Ventilator-associated Pneumonia
  • 7.6. Aspiration Pneumonia

8. By Treatment

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 8.1.2. Market Attractiveness Index, By Treatment
  • 8.2. Prevention Vaccines *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Antibacterial Drugs
    • 8.3.1. Delafloxacin (Baxdela)
    • 8.3.2. Azithromycin (Zithromax)
    • 8.3.3. Aztreonam (Azactam)
    • 8.3.4. Ertapenem (Invanz)
    • 8.3.5. Others
  • 8.4. Antifungal Drugs
    • 8.4.1. Itraconazole
    • 8.4.2. Fluconazole
    • 8.4.3. Triazoles
    • 8.4.4. Others
  • 8.5. Antiviral Drugs
    • 8.5.1. Ribavirin
    • 8.5.2. Amantadine
    • 8.5.3. Acyclovir
    • 8.5.4. Others

9. By Route of Administration

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 9.1.2. Market Attractiveness Index, By Route of Administration
  • 9.2. Oral*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Parenteral
  • 9.4. Others

10. By Distribution Channel

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.1.2. Market Attractiveness Index, By Distribution Channel
  • 10.2. Hospital Pharmacy*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Retail Pharmacy
  • 10.4. Online Pharmacy

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 11.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 11.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 11.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 11.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. U.K.
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

12. Competitive Landscape

  • 12.1. Competitive Scenario
  • 12.2. Product Benchmarking
  • 12.3. Company Share Analysis
  • 12.4. Key Developments and Strategies

13. Company Profiles

  • 13.1. Pfizer Inc.*
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Financial Overview
    • 13.1.4. Key Developments
  • 13.2. Dr. Reddy's Laboratories
  • 13.3. LGM Pharma LLC
  • 13.4. Teva Pharmaceuticals Ltd.
  • 13.5. AdvaCare Pharma
  • 13.6. Baxter International Inc.
  • 13.7. Innoviva Specialty Therapeutics Inc.
  • 13.8. F. Hoffmann-La Roche Ltd
  • 13.9. Sanofi S.A
  • 13.10. Lupin Limited

LIST NOT EXHAUSTIVE

14. Appendix

  • 14.1. About Us and Services
  • 14.2. Contact Us